Summary
Vertex Pharmaceuticals Incorporated (VRTX) announced on November 19, 2020, a new share repurchase program authorized by its Board of Directors. This program allows the company to buy back up to $500.0 million of its common stock, with the authority extending through December 31, 2022. The repurchases can be executed through various methods, including open market transactions or privately negotiated deals, subject to prevailing business and market conditions, and other investment considerations.
Key Highlights
- 1Vertex Pharmaceuticals has authorized a new share repurchase program valued at up to $500.0 million.
- 2The new repurchase program is authorized through December 31, 2022.
- 3Repurchases can occur on the open market or via privately negotiated transactions, including Rule 10b5-1 plans.
- 4The company completed its previous $500.0 million share repurchase program, authorized in 2019, as of October 19, 2020.
- 5This indicates continued confidence by the Board in the company's financial health and future prospects.
Frequently Asked Questions
The main purpose is to announce Vertex Pharmaceuticals' Board of Directors has authorized a new program to repurchase up to $500.0 million of its common stock, signaling management's belief in the company's value and commitment to returning capital to shareholders.
The new repurchase program is authorized to continue through December 31, 2022.
Vertex may repurchase its stock from time to time on the open market or through privately negotiated transactions, including the use of Rule 10b5-1 plans, depending on market conditions and other business opportunities.
Yes, Vertex had a previous share repurchase program authorized in 2019 for up to $500.0 million, which was fully completed as of October 19, 2020, prior to the announcement of this new program.